|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:China
gptkb:Europe
gptkb:France
gptkb:India
1990s
|
|
gptkbp:ATCCode
|
N05AL05
|
|
gptkbp:brand
|
Solian
Amipride
Amitrex
Amodal
Barhemsys
Deniban
Socian
Soltus
Sulpitac
|
|
gptkbp:CASNumber
|
71675-85-9
|
|
gptkbp:chemicalFormula
|
C17H27N3O4S
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:drugClass
|
gptkb:antipsychotic_medication
benzamide
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:IUPACName
|
4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
|
|
gptkbp:KEGGID
|
gptkb:D07451
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
dopamine D3 receptor antagonist
|
|
gptkbp:metabolism
|
minimal hepatic metabolism
|
|
gptkbp:molecularWeight
|
369.48 g/mol
|
|
gptkbp:PubChem_CID
|
2159
CHEMBL1407
DB06210
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:hyperprolactinemia
gptkb:sexual_dysfunction
nausea
anxiety
constipation
weight gain
insomnia
extrapyramidal symptoms
|
|
gptkbp:UNII
|
7T59J1MMK7
|
|
gptkbp:usedFor
|
schizophrenia
acute psychosis
depression (off-label)
|
|
gptkbp:bfsParent
|
gptkb:N05AX
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
amisulpride
|